Cascade Prodrug Overview
- Year Founded
-
2009

- Status
-
Private
- Employees
-
4

- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$450K
- Investors
-
14
Cascade Prodrug General Information
Description
Developer of chemotherapy technology designed to treat a variety of solid tumor indications. The company's technology specializes in the advantage of tumor hypoxia and triggers drug conversion in the tumor where it's needed, thus limiting the exposure of healthy tissue to a potent cytotoxic agent, enabling cancer patients to experience an improved safety profile relative to currently approved chemotherapy agents.
Contact Information
Website
www.cascadeprodrug.comCorporate Office
- Post Office Box 13020
- Eugene, OR 97440
- United States
Corporate Office
- Post Office Box 13020
- Eugene, OR 97440
- United States
Cascade Prodrug Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Later Stage VC (Series B) | 06-Apr-2020 | $450K | Completed | Generating Revenue | ||
6. Later Stage VC | 03-Jun-2016 | Completed | Generating Revenue | |||
5. Later Stage VC | 03-Apr-2015 | Completed | Generating Revenue | |||
4. Early Stage VC (Series A) | 01-Apr-2013 | Completed | Generating Revenue | |||
3. Grant | 11-May-2012 | Completed | Generating Revenue | |||
2. Early Stage VC | 14-Feb-2012 | $400K | $400K | Completed | Generating Revenue | |
1. Grant | 29-Oct-2010 | $244K | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cascade Prodrug Patents
Cascade Prodrug Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4267136-A1 | Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor | Pending | 23-Dec-2020 | ||
US-20240139175-A1 | Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor | Pending | 23-Dec-2020 | ||
EP-4267136-A4 | Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor | Pending | 23-Dec-2020 | ||
US-20100016252-A1 | Mannich base n-oxide drugs | Active | 19-Mar-2007 | ||
US-8410075-B2 | Mannich base n-oxide drugs | Active | 19-Mar-2007 | C07C291/04 |
Cascade Prodrug Signals
Cascade Prodrug Investors (14)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Elevate Capital | Venture Capital | Minority | ||
Angel (individual) | Minority | |||
Angel (individual) | Minority | |||
Angel (individual) | Minority | |||
Angel (individual) | Minority |
Cascade Prodrug FAQs
-
When was Cascade Prodrug founded?
Cascade Prodrug was founded in 2009.
-
Where is Cascade Prodrug headquartered?
Cascade Prodrug is headquartered in Eugene, OR.
-
What is the size of Cascade Prodrug?
Cascade Prodrug has 4 total employees.
-
What industry is Cascade Prodrug in?
Cascade Prodrug’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Cascade Prodrug a private or public company?
Cascade Prodrug is a Private company.
-
What is Cascade Prodrug’s current revenue?
The current revenue for Cascade Prodrug is
. -
How much funding has Cascade Prodrug raised over time?
Cascade Prodrug has raised $2.57M.
-
Who are Cascade Prodrug’s investors?
Elevate Capital, , , , and are 5 of 14 investors who have invested in Cascade Prodrug.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »